Vitamin B12 uptake by intestinal microorganisms: mechanism and relevance to syndromes of intestinal bacterial overgrowth.
The mechanism of bacterial uptake of vitamin B(12), the spectrum of microorganisms capable of such uptake, and the factors involved were the subject of this study. Bacterial uptake of vitamin B(12) was found to be at least a two stage process. A primary uptake phase which was rapid (1 min or less), pH dependent, nontemperature dependent, did not require viable organisms and was insensitive to either the metabolic inhibitor dinitrophenol or to the sulfhydryl inhibitor N-ethyl-maleimide. Protein denaturation (formalin treatment or autoclaving) abolished all B(12) uptake. This primary uptake phase is thought to represent adsorption to binding or "receptor" sites on the cell wall. Second stage uptake was slower, pH and temperature dependent, required living bacteria, and was abolished by either dinitrophenol or N-ethyl-maleimide. This phase is dependent upon metabolic processes and may reflect transfer of B(12) from surface "receptor" sites into the bacterial cell. Although differences among organisms were observed in total 1 hr uptake, number of surface "receptor" sites, and relative avidities for B(12), all organisms except Streptococcus fecalis shared the two stage mechanism. Two Gram-positive organisms. Bacillus subtilis and Group A streptococcus, demonstrated the highest 1 hr vitamin B(12) uptake values; Gram-negative bacteria required 2,000-10,000 the number of organisms for comparable uptake. Binding constants (K(m)) varied from 5.05 +/-1.67 x 10(-10)M for B. subtilis to 6.18 +/-3.08 x 10(-9)M for Klebsiella pneumoniae which approximate the Km for human intrinsic factor (0.38 x 10(-10)M). Competition between bacteria and intrinsic factor for vitamin B(12) may be inferred from the similarity of these constants. These observations suggest that a variety of enteric and nonenteric organisms, not requiring exogenous B(12), may play a role in the pathogenesis of the vitamin B(12) malabsorption found in the intestinal bacterial overgrowth syndromes.
D001412:Bacillus subtilis / Q000378:metabolism; D001419:Bacteria / Q000378:metabolism*; D003864:Depression, Chemical; D004140:Dinitrophenols / Q000494:pharmacology; D013293:Enterococcus faecalis / Q000378:metabolism; D004926:Escherichia coli / Q000378:metabolism; D005033:Ethylmaleimide / Q000494:pharmacology; D005557:Formaldehyde / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D007422:Intestines / Q000382:microbiology*; D007700:Kinetics; D008286:Malabsorption Syndromes / Q000209:etiology; D011511:Proteus / Q000378:metabolism; D011550:Pseudomonas aeruginosa / Q000378:metabolism; D012482:Salmonella paratyphi A / Q000378:metabolism; D013210:Staphylococcus / Q000378:metabolism; D013291:Streptococcus / Q000378:metabolism; D013696:Temperature; D014805:Vitamin B 12 / Q000378:metabolism*
D004140:Dinitrophenols; D005557:Formaldehyde; D005033:Ethylmaleimide; D014805:Vitamin B 12